Bo Tuo Biological 400 million product upgrade projects are expected to reach production in 2024

"Science and Technology Board Daily" September 28 news, Hangzhou Botuo Biotechnology Co., Ltd. disclosed the investigation discipline to show that the company's annual output of 400 million people (in vitro diagnostic) product expansion and upgrading construction projects are expected to be partially reached in 2023 The production capacity of 240 million people will be reached in 2024. The company has developed monkey acne virus antigen and antibody fast detection reagents, monkey acne virus nucleic acid detection agents (fluorescent PCR method) and has obtained CE certification. Some customers have received samples to some customers. There are many foreign exchange on the company's account, and the appreciation of the US dollar has a positive impact on the company's financial statements.

According to public information, Hangzhou Botuo Biotechnology Co., Ltd. was founded in 2008. It is a national high -tech enterprise specializing in the research and development, manufacturing, sales and service of internal diagnostic reagents, raw materials and instruments. At present, there are more than a hundred products in Boruo, and the business covers more than 100 countries and regions around the world, and has served more than 3 billion people. Bo Tuo products cover multiple areas of medical testing, and have five series of infectious disease testing, drug abuse (drug) testing, tumor logo testing, myocardial logo detection, and reproductive health test. Stations, banned detoxification and third -party inspection agencies are widely used. The company has passed the German TUV ISO13485 quality system certification. Many products have China NMPA registration, EU CE certification, and the US FDA 510 (K) certificate.

Bo Tuo Biological has established an industrialized technology platform such as a rapid immunoaged diagnosis platform, POCT application technology platform, biological core raw material technology platform, and automated production technology platform. Based on this Hundreds of products in the five major products series of five major products such as infectious disease testing, tumor logo testing, and myocardial logo testing are widely used in medical institutions at all levels at home and abroad, judicial testing systems, third -party testing institutions, disease prevention and control centers, and blood collection stations , Private clinic, etc.

Smart bud data shows that Hangzhou Botuo Biotechnology Co., Ltd. and its related companies have applied for nearly 260 patents, of which more than 70 invention patents, accounting for more than 26%. The company has a patented technology layout in China, the United States, Australia, Mexico, Europe and other countries/regions. By further analyzing its patented technology data, the company's patented technology is mainly deployed in the fields of liquid samples, test elements, three -dimensional diagrams, seal elements and other fields.

- END -